Beth-Ann Coller

1.9k total citations
26 papers, 1.1k citations indexed

About

Beth-Ann Coller is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Epidemiology. According to data from OpenAlex, Beth-Ann Coller has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 10 papers in Public Health, Environmental and Occupational Health and 8 papers in Epidemiology. Recurrent topics in Beth-Ann Coller's work include Viral Infections and Vectors (19 papers), Viral Infections and Outbreaks Research (18 papers) and Mosquito-borne diseases and control (10 papers). Beth-Ann Coller is often cited by papers focused on Viral Infections and Vectors (19 papers), Viral Infections and Outbreaks Research (18 papers) and Mosquito-borne diseases and control (10 papers). Beth-Ann Coller collaborates with scholars based in United States, Australia and United Kingdom. Beth-Ann Coller's co-authors include David E. Clements, Andrew J. Bett, Jan H. ter Meulen, Sangeetha L. Sagar, Sheri Dubey, Jakub K. Simon, Tom Humphreys, Gary S. Bignami, Jayanthi Wolf and J. Robert Putnak and has published in prestigious journals such as Journal of Virology, The Journal of Infectious Diseases and Cell Reports.

In The Last Decade

Beth-Ann Coller

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth-Ann Coller United States 17 771 668 206 105 77 26 1.1k
Annick Moureau France 12 705 0.9× 875 1.3× 172 0.8× 55 0.5× 95 1.2× 29 1.1k
Chukiat Sirivichayakul Thailand 22 1.1k 1.4× 1.5k 2.2× 219 1.1× 88 0.8× 115 1.5× 57 1.9k
Gajanan Sapkal India 22 950 1.2× 549 0.8× 226 1.1× 164 1.6× 30 0.4× 75 1.2k
Kriengsak Limkittikul Thailand 21 1.2k 1.5× 1.7k 2.5× 219 1.1× 130 1.2× 138 1.8× 66 2.0k
Ruklanthi de Alwis Singapore 19 1.3k 1.7× 1.1k 1.7× 190 0.9× 163 1.6× 125 1.6× 40 1.7k
Alienys Izquierdo Cuba 14 659 0.9× 864 1.3× 108 0.5× 76 0.7× 73 0.9× 21 973
Vianney Tricou United States 15 1.0k 1.4× 1.1k 1.7× 107 0.5× 58 0.6× 68 0.9× 44 1.4k
Louis Macareo Thailand 16 621 0.8× 795 1.2× 126 0.6× 66 0.6× 48 0.6× 44 1.0k
T. Anh Wartel South Korea 15 816 1.1× 973 1.5× 88 0.4× 45 0.4× 97 1.3× 29 1.1k
Audrey Dubot‐Pérès France 18 592 0.8× 537 0.8× 142 0.7× 71 0.7× 37 0.5× 56 931

Countries citing papers authored by Beth-Ann Coller

Since Specialization
Citations

This map shows the geographic impact of Beth-Ann Coller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth-Ann Coller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth-Ann Coller more than expected).

Fields of papers citing papers by Beth-Ann Coller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth-Ann Coller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth-Ann Coller. The network helps show where Beth-Ann Coller may publish in the future.

Co-authorship network of co-authors of Beth-Ann Coller

This figure shows the co-authorship network connecting the top 25 collaborators of Beth-Ann Coller. A scholar is included among the top collaborators of Beth-Ann Coller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth-Ann Coller. Beth-Ann Coller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bixler, Sandra L., Amy C. Shurtleff, Kenneth Liu, et al.. (2025). Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model. Viruses. 17(3). 342–342.
2.
Gunn, Bronwyn M., Ryan P. McNamara, Wenyu Guo, et al.. (2023). Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. Cell Reports. 42(4). 112402–112402. 12 indexed citations
3.
Coller, Beth-Ann, William Lapps, Samantha Bruno, et al.. (2022). Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. Vaccines. 10(9). 1446–1446. 6 indexed citations
4.
Simon, Jakub K., Stephen B. Kennedy, Barbara E. Mahon, et al.. (2022). Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine. 40(46). 6599–6606. 11 indexed citations
5.
Grais, Rebecca F., Stephen B. Kennedy, Barbara E. Mahon, et al.. (2021). Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. The Lancet Microbe. 2(2). e70–e78. 17 indexed citations
6.
Wolf, Jayanthi, Sheri Dubey, Sean P. Troth, et al.. (2021). Development of Pandemic Vaccines: ERVEBO Case Study. Vaccines. 9(3). 190–190. 40 indexed citations
7.
Wolf, Jayanthi, et al.. (2020). Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. npj Vaccines. 5(1). 51–51. 37 indexed citations
8.
Tell, Joan G., Beth-Ann Coller, Sheri Dubey, et al.. (2020). Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease. Vaccines. 8(4). 779–779. 7 indexed citations
9.
10.
Halperin, Scott A., Rituparna Das, Matthew Onorato, et al.. (2019). Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. The Journal of Infectious Diseases. 220(7). 1127–1135. 34 indexed citations
11.
Greenberg, David, Timo Vesikari, David Hurley, et al.. (2018). Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 36(45). 6883–6891. 78 indexed citations
12.
Coller, Beth-Ann, Jeffrey T. Blue, Rituparna Das, et al.. (2017). Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 35(35). 4465–4469. 35 indexed citations
13.
Manoff, Susan B., Sarah L. George, Andrew J. Bett, et al.. (2015). Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine. 33(50). 7126–7134. 51 indexed citations
14.
Govindarajan, Dhanasekaran, Liming Guan, David E. Clements, et al.. (2015). Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates. Vaccine. 33(33). 4105–4116. 59 indexed citations
15.
Hermann, Laura L., et al.. (2014). Advances in the understanding, management, and prevention of dengue. Journal of Clinical Virology. 64. 153–159. 33 indexed citations
16.
Liu, Heng, Laura Bungener, Wouter ter Veer, et al.. (2011). Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine. 29(11). 2037–2043. 21 indexed citations
17.
Coller, Beth-Ann & David E. Clements. (2011). Dengue vaccines: progress and challenges. Current Opinion in Immunology. 23(3). 391–398. 101 indexed citations
18.
Coller, Beth-Ann, David E. Clements, Andrew J. Bett, Sangeetha L. Sagar, & Jan H. ter Meulen. (2011). The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 29(42). 7267–7275. 116 indexed citations
19.
Clements, David E., Beth-Ann Coller, Michael M. Lieberman, et al.. (2010). Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine. 28(15). 2705–2715. 160 indexed citations
20.
Putnak, J. Robert, Beth-Ann Coller, Gérald Voss, et al.. (2005). An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine. 23(35). 4442–4452. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annick Moureau Breakdown of academic impact, for papers by Chukiat Sirivichayakul Breakdown of academic impact, for papers by Gajanan Sapkal Breakdown of academic impact, for papers by Kriengsak Limkittikul Breakdown of academic impact, for papers by Ruklanthi de Alwis Breakdown of academic impact, for papers by Alienys Izquierdo Breakdown of academic impact, for papers by Vianney Tricou Breakdown of academic impact, for papers by Louis Macareo Breakdown of academic impact, for papers by T. Anh Wartel Breakdown of academic impact, for papers by Audrey Dubot‐Pérès
Rankless by CCL
2026